Research programme: melanocortin 4 receptor agonists - Palatin Technologies/AstraZeneca

Drug Profile

Research programme: melanocortin 4 receptor agonists - Palatin Technologies/AstraZeneca

Alternative Names: PT 15

Latest Information Update: 23 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Palatin Technologies
  • Developer Palatin Technologies
  • Class Metals; Peptides; Small molecules
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Metabolic syndrome; Obesity

Most Recent Events

  • 09 Feb 2017 Preclinical development in Diabetes mellitus, Metabolic syndrome and Obesity is ongoing in USA
  • 29 Sep 2015 Palatin terminates its research collaboration and license agreement with AstraZeneca for melanocortin 4 receptor agonists in USA
  • 11 Dec 2008 Palatin and AstraZeneca extend their research collaboration and licensing agreement for compounds targeting melanocortin receptors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top